What could be causing intermittent jaundice (yellowing of the sclera) in a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intermittent Jaundice (Yellowing of Sclera): Differential Diagnosis and Evaluation

Most Likely Causes

Intermittent jaundice suggests either relapsing hepatobiliary disease, intermittent biliary obstruction, or episodic hemolysis rather than progressive liver failure. The pattern of "on and off" yellowing narrows the differential significantly compared to persistent jaundice.

Primary Diagnostic Considerations

Relapsing Hepatitis A is a well-documented cause of intermittent jaundice, occurring in 10-15% of hepatitis A cases with relapses lasting up to 6 months, and approximately 20% of these patients experience multiple relapses 1. Hepatitis A virus can be detected in stool during relapses, and despite the relapsing nature, overall outcomes remain very good 1.

Intermittent biliary obstruction from choledocholithiasis (common bile duct stones) commonly presents with fluctuating jaundice as stones intermittently obstruct then pass or shift position 1. This represents 13-14% of severe jaundice cases and is one of the most common obstructive causes 1.

Cholestatic hepatitis can present with prolonged or intermittent jaundice, particularly in the context of hepatitis A or drug-induced liver injury 1.

Hemolytic episodes can cause intermittent unconjugated hyperbilirubinemia, particularly in Wilson's disease where acute hemolytic episodes may occur as single events or recurrently 1. Hemolysis was a presenting feature in 12% of Wilson's disease cases in one series 1.

Diagnostic Algorithm

Step 1: Initial Laboratory Evaluation

Obtain fractionated bilirubin (conjugated vs unconjugated), complete blood count, AST, ALT, alkaline phosphatase, GGT, albumin, PT/INR 2, 3. This determines whether hyperbilirubinemia is conjugated (suggesting hepatobiliary disease) or unconjugated (suggesting hemolysis or Gilbert syndrome) 1, 2.

  • Unconjugated hyperbilirubinemia points toward hemolysis, hematoma resorption, or Gilbert syndrome 4, 5
  • Conjugated hyperbilirubinemia indicates hepatocellular disease, biliary obstruction, or cholestatic processes 1, 4
  • Elevated alkaline phosphatase suggests biliary obstruction or infiltrative disease 6
  • Elevated transaminases indicate hepatocellular injury from viral hepatitis, drug toxicity, or autoimmune disease 6

Step 2: First-Line Imaging

Abdominal ultrasound is mandatory as the initial imaging test for all patients with jaundice 1, 7. Ultrasound is designated by the American College of Radiology as first-line due to its non-invasive nature, lack of radiation, low cost, and rapid availability 7.

Ultrasound will:

  • Detect biliary ductal dilatation (sensitivity 32-100%, specificity 71-97%) 1, 7
  • Identify gallstones with 96% accuracy 7
  • Detect cirrhosis (sensitivity 65-95%, positive predictive value 98%) 1
  • Assess for portal hypertension and ascites 7

Critical caveat: Ultrasound has limited sensitivity (22.5-75%) for common bile duct stones because the distal duct may be obscured by bowel gas 1. Normal ultrasound does not exclude choledocholithiasis if clinical suspicion remains high 7.

Step 3: Advanced Imaging When Indicated

If ultrasound shows biliary obstruction or is inconclusive, proceed to MRCP 1, 7. MRCP has pooled sensitivity of 86% and specificity of 94% for diagnosing biliary pathology including primary sclerosing cholangitis 1.

If biliary obstruction is confirmed and therapeutic intervention needed, ERCP is appropriate 1, 7. However, ERCP carries risks including pancreatitis (1.3-1.5% of cases, 70% mild), cholangitis (<1%), and perforation 1.

Step 4: Specific Disease Considerations

For suspected relapsing hepatitis A: Check hepatitis A IgM and IgG serology 1. Patients typically improve within 3-4 weeks but 10-15% have relapsing disease 1. A short course of rapidly tapered corticosteroids can reduce symptoms in cholestatic hepatitis 1.

For suspected choledocholithiasis: The presence of multiple small (<5 mm) gallstones creates 4-fold risk for CBD migration 1. If ultrasound is negative but suspicion high, proceed to MRCP or endoscopic ultrasound 7.

For suspected hemolysis: Check Coombs test, LDH, haptoglobin, and reticulocyte count 1, 4. Consider Wilson's disease in younger patients, particularly if accompanied by neurologic symptoms or Kayser-Fleischer rings 1.

For suspected primary sclerosing cholangitis: Look for concomitant inflammatory bowel disease (present in 50-80% of PSC cases) and persistently elevated alkaline phosphatase 1. MRCP is the preferred diagnostic test showing multifocal strictures and dilatations 1.

Critical Pitfalls to Avoid

Do not assume normal ultrasound excludes significant pathology 7. If clinical suspicion remains high despite negative ultrasound, proceed to MRCP or endoscopic ultrasound, particularly for suspected choledocholithiasis 7.

Do not delay evaluation of new or worsening jaundice in patients with known PSC, as this may indicate cholangiocarcinoma, which has a lifetime risk of up to 20% in PSC patients 1. Rapidly increasing jaundice, weight loss, or elevated CA 19-9 warrant urgent cross-sectional imaging and possible ERCP with tissue sampling 1.

Do not attribute jaundice solely to "hepatic encephalopathy" in cirrhotic patients without excluding acute processes such as sepsis (22% of new-onset jaundice), decompensated cirrhosis (20.5%), or biliary obstruction 1.

Recognize that intermittent jaundice from biliary obstruction may resolve spontaneously as stones pass, but this does not eliminate the need for definitive evaluation and treatment to prevent recurrence and complications like cholangitis 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Evaluation of Jaundice in Adults.

American family physician, 2025

Research

A Systematic Approach to Patients with Jaundice.

Seminars in interventional radiology, 2016

Research

Jaundice in the adult patient.

American family physician, 2004

Guideline

Indications for Hepatobiliary-Pancreas Ultrasound

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the appropriate evaluation and management for a patient presenting with jaundice and generalized weakness?
What specific questions should I ask a patient with jaundice and right upper quadrant pain during clerking?
What are the causes of jaundice?
What are the initial tests for diagnosing jaundice?
What is the likely diagnosis for a 25-year-old female patient with icteric sclera, elevated total, indirect, and direct bilirubins, and ultrasound findings of a diffusely increased liver parenchymal echogenicity, smooth hepatic contour, and multiple tiny mobile shadowing echogenic foci within the gallbladder, without abdominal pain, fever, or nausea?
Is a 5mm clearance sufficient for surgical excision of melanoma in situ?
What is the recommended dosage and treatment duration of vancomycin (generic name) for a 10-11kg child with suspected infection?
What is the initial recommended dose of metformin (biguanide) for a typical adult patient with type 2 diabetes mellitus?
What is the management approach for a patient suspected of having a hemorrhagic conversion, particularly in terms of imaging, blood pressure control, and potential surgical intervention?
What are the management options for a patient with severely impaired renal function, indicated by an estimated Glomerular Filtration Rate (eGFR) of 13, elevated creatinine levels, increased albuminuria, and uremia, likely with chronic kidney disease stage 5 and potential comorbidities such as hypertension and diabetes?
Should a 20-year-old with hypercholesterolemia, hyperlipidemia, normal HDL-C and triglyceride levels, and no cardiovascular risk factors start statin (HMG-CoA reductase inhibitor) therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.